- Investing Ideas
- South Korean Pharmaceuticals & Biotech Healthy potentially undervalued
South Korean Pharmaceuticals & Biotech Healthy potentially undervalued
Results
6
Companies which are potentially undervalued and in an acceptable financial position.
6 companies
Hugel
Market Cap: ₩2.8t
Develops and manufactures biopharmaceuticals in South Korea and internationally.
A145020
₩258,000.00
7D
7.7%
1Y
-32.8%
Dong-A Socio Holdings
Market Cap: ₩557.5b
Engages in the pharmaceutical business in South Korea.
A000640
₩84,100.00
7D
1.8%
1Y
-29.6%
Dong-A ST
Market Cap: ₩358.1b
Develops, manufactures, and markets pharmaceutical products in South Korea and internationally.
A170900
₩37,250.00
7D
2.8%
1Y
-18.2%
Daewoong Pharmaceutical
Market Cap: ₩1.4t
Develops, manufactures and commercializes pharmaceutical products in South Korea and internationally.
A069620
₩123,500.00
7D
2.2%
1Y
-20.7%
PharmaResearch
Market Cap: ₩3.1t
Operates as a biopharmaceutical company primarily in South Korea.
A214450
₩302,000.00
7D
7.3%
1Y
-30.1%
ST PharmLtd
Market Cap: ₩2.8t
Provides manufacturing services for active pharmaceutical ingredient and intermediate.
A237690
₩133,000.00
7D
12.9%
1Y
70.5%